BACKGROUND: Salivary duct carcinoma (SDC) is an aggressive tumor of the head and neck with a poor prognosis. The objective was to study SDC and recommend the use of trastuzumab as adjuvant therapy. METHODS: A retrospective chart review of patients seen between 1993 and 2006 was performed. Tumor specimens were examined for HER-2 protein overexpression via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) methods. RESULTS: Of the 7 patients with SDC, 57% had tumors arising in the parotid gland, the majority having facial nerve paralysis, 71% with nodal disease, and 43% having recurrence. All samples were HER-2 positive on IHC. Three patients had FISH-positive tumors, recurrent disease, and received trastuzumab therapy; 1 of the 3 died after 20 months and a second has shown disappearance of metastatic disease. CONCLUSIONS: Trastuzumab is effective in treating HER-2-positive breast cancer. Given immunohistochemical similarities between SDC and ductal carcinoma of the breast, patients with FISH-positive HER-2/neu SDC should be considered for trastuzumab therapy.
BACKGROUND:Salivary duct carcinoma (SDC) is an aggressive tumor of the head and neck with a poor prognosis. The objective was to study SDC and recommend the use of trastuzumab as adjuvant therapy. METHODS: A retrospective chart review of patients seen between 1993 and 2006 was performed. Tumor specimens were examined for HER-2 protein overexpression via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) methods. RESULTS: Of the 7 patients with SDC, 57% had tumors arising in the parotid gland, the majority having facial nerve paralysis, 71% with nodal disease, and 43% having recurrence. All samples were HER-2 positive on IHC. Three patients had FISH-positive tumors, recurrent disease, and received trastuzumab therapy; 1 of the 3 died after 20 months and a second has shown disappearance of metastatic disease. CONCLUSIONS:Trastuzumab is effective in treating HER-2-positive breast cancer. Given immunohistochemical similarities between SDC and ductal carcinoma of the breast, patients with FISH-positive HER-2/neu SDC should be considered for trastuzumab therapy.
Authors: Elina Salovaara; Olli Hakala; Leif Bäck; Petri Koivunen; Kauko Saarilahti; Fabricio Passador-Santos; Ilmo Leivo; Antti A Mäkitie Journal: Eur Arch Otorhinolaryngol Date: 2012-03-22 Impact factor: 2.503
Authors: Sewanti A Limaye; Marshall R Posner; Jeffrey F Krane; Maria Fonfria; Jochen H Lorch; Deborah A Dillon; Aditya V Shreenivas; Roy B Tishler; Robert I Haddad Journal: Oncologist Date: 2013-02-21
Authors: Moran Amit; Ayelet Eran; Salem Billan; Eran Fridman; Shorook Na'ara; Tomer Charas; Ziv Gil Journal: J Neurol Surg B Skull Base Date: 2016-02-26
Authors: Tiziana Negri; Elena Tamborini; Gian Paolo Dagrada; Angela Greco; Samantha Staurengo; Marco Guzzo; Laura D Locati; Antonino Carbone; Marco A Pierotti; Lisa Licitra; Silvana Pilotti Journal: Transl Oncol Date: 2008-09 Impact factor: 4.243